ACR 174: Hepatitis Awareness Month and Hepatitis Testing Day.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-06-13
This measure would proclaim the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
This measure would proclaim the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
This measure would proclaim the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
This measure would proclaim the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
WHEREAS, Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California; and
WHEREAS, Hepatitis C is the most prevalent bloodborne disease in the United States and in California; and
WHEREAS, Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives; and
WHEREAS, An undetected and untreated hepatitis B or C infection can lead to disability or death; and
WHEREAS, The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, Untreated hepatitis B and C infections are the leading causes of liver failure requiring a liver transplant; and
WHEREAS, While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C-related death toll now exceeds all other nationally notifiable infectious conditions combined; and
WHEREAS, Between 2011 and 2015, rates of newly reported hepatitis C infections increased 37 percent among females between 20 and 29 years of age, and 55 percent among males in that age range, and increased 40 percent among males between 15 and 19 years of age; and
WHEREAS, Each year, hepatitis B and C cause nearly 1.5 million deaths worldwidemore than HIV, tuberculosis, and malaria; and
WHEREAS, On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030; and
WHEREAS, The federal Centers for Disease Control and Prevention released updated guidelines calling for baby boomerseveryone born between 1945 and 1965to receive a one-time hepatitis C test, which would save over 100,000 lives; and
WHEREAS, In 2013, the United States Preventive Services Task Force (USPSTF) issued a Grade B rating for screening for hepatitis C virus (HCV) infection in persons at high risk for infection and adults born between 1945 and 1965; and
WHEREAS, Baby boomers make up 30 percent of Californias adult population, and African American baby boomers are twice as likely to have hepatitis C as other baby boomers; and
WHEREAS, In 2009, the USPSTF issued a Grade A rating for screening pregnant women for the hepatitis B virus (HBV) infection during their first prenatal visit; and
WHEREAS, In 2014, the USPSTF issued a Grade B rating for screening people born in countries where hepatitis B is common, United States-born people who were not vaccinated against hepatitis B when they were babies and whose parents come from countries where hepatitis B is common, and other people at risk for hepatitis B; and
WHEREAS, There is a vaccine for the prevention of hepatitis Bthe first proven, low-cost vaccination against any form of cancer made available to Americans; and
WHEREAS, Hepatitis B is most prevalent among people of Asian and Pacific Islander descent, and one-third of Americans of Asian and Pacific Islander descent live in California; and
WHEREAS, Hepatitis B-related and hepatitis C-related hospitalization charges totaled $2.3 billion in 2010 in California, mostly paid for by tax-supported public health insurers; and
WHEREAS, New medications can cure hepatitis C in over 90 percent of people who are linked to and retained in care and treatment; and
WHEREAS, Hepatitis B can be treated effectively with proper medical management and may be curable in the near future; and
WHEREAS, The Legislature will continue to work to increase the affordability of, and access to, care, treatment, and cures for hepatitis; and
WHEREAS, Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California; and
WHEREAS, Hepatitis C is the most prevalent bloodborne disease in the United States and in California; and
WHEREAS, Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives; and
WHEREAS, An undetected and untreated hepatitis B or C infection can lead to disability or death; and
WHEREAS, The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, Untreated hepatitis B and C infections are the leading causes of liver failure requiring a liver transplant; and
WHEREAS, While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C-related death toll now exceeds all other nationally notifiable infectious conditions combined; and
WHEREAS, Between 2011 and 2015, rates of newly reported hepatitis C infections increased 37 percent among females between 20 and 29 years of age, and 55 percent among males in that age range, and increased 40 percent among males between 15 and 19 years of age; and
WHEREAS, Each year, hepatitis B and C cause nearly 1.5 million deaths worldwidemore than HIV, tuberculosis, and malaria; and
WHEREAS, On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030; and
WHEREAS, The federal Centers for Disease Control and Prevention released updated guidelines calling for baby boomerseveryone born between 1945 and 1965to receive a one-time hepatitis C test, which would save over 100,000 lives; and
WHEREAS, In 2013, the United States Preventive Services Task Force (USPSTF) issued a Grade B rating for screening for hepatitis C virus (HCV) infection in persons at high risk for infection and adults born between 1945 and 1965; and
WHEREAS, Baby boomers make up 30 percent of Californias adult population, and African American baby boomers are twice as likely to have hepatitis C as other baby boomers; and
WHEREAS, In 2009, the USPSTF issued a Grade A rating for screening pregnant women for the hepatitis B virus (HBV) infection during their first prenatal visit; and
WHEREAS, In 2014, the USPSTF issued a Grade B rating for screening people born in countries where hepatitis B is common, United States-born people who were not vaccinated against hepatitis B when they were babies and whose parents come from countries where hepatitis B is common, and other people at risk for hepatitis B; and
WHEREAS, There is a vaccine for the prevention of hepatitis Bthe first proven, low-cost vaccination against any form of cancer made available to Americans; and
WHEREAS, Hepatitis B is most prevalent among people of Asian and Pacific Islander descent, and one-third of Americans of Asian and Pacific Islander descent live in California; and
WHEREAS, Hepatitis B-related and hepatitis C-related hospitalization charges totaled $2.3 billion in 2010 in California, mostly paid for by tax-supported public health insurers; and
WHEREAS, New medications can cure hepatitis C in over 90 percent of people who are linked to and retained in care and treatment; and
WHEREAS, Hepatitis B can be treated effectively with proper medical management and may be curable in the near future; and
WHEREAS, The Legislature will continue to work to increase the affordability of, and access to, care, treatment, and cures for hepatitis; and
WHEREAS, Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California; and
WHEREAS, Hepatitis C is the most prevalent bloodborne disease in the United States and in California; and
WHEREAS, Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives; and
WHEREAS, An undetected and untreated hepatitis B or C infection can lead to disability or death; and
WHEREAS, The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, Untreated hepatitis B and C infections are the leading causes of liver failure requiring a liver transplant; and
WHEREAS, While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C-related death toll now exceeds all other nationally notifiable infectious conditions combined; and
WHEREAS, Between 2011 and 2015, rates of newly reported hepatitis C infections increased 37 percent among females between 20 and 29 years of age, and 55 percent among males in that age rage, range, and increased 40 percent among males between 15 and 19 years of age; and
WHEREAS, Each year, hepatitis B and C cause nearly 1.5 million deaths worldwidemore than HIV, tuberculosis, and malaria; and
WHEREAS, On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030; and
WHEREAS, The federal Centers for Disease Control and Prevention released updated guidelines calling for baby boomerseveryone born between 1945 and 1965to receive a one-time hepatitis C test, which would save over 100,000 lives; and
WHEREAS, In 2013, the United States Preventive Services Task Force (USPSTF) issued a Grade B rating for screening for hepatitis C virus (HCV) infection in persons at high risk for infection and adults born between 1945 and 1965; and
WHEREAS, Baby boomers make up 30 percent of Californias adult population, and African American baby boomers are twice as likely to have hepatitis C as other baby boomers; and
WHEREAS, In 2009, the USPSTF issued a Grade A rating for screening pregnant women for the hepatitis B virus (HBV) infection during their first prenatal visit; and
WHEREAS, In 2014, the USPSTF issued a Grade B rating for screening people born in countries where hepatitis B is common, United States-born people who were not vaccinated against hepatitis B when they were babies and whose parents come from countries where hepatitis B is common, and other people at risk for hepatitis B; and
WHEREAS, There is a vaccine for the prevention of hepatitis Bthe first proven, low-cost vaccination against any form of cancer made available to Americans; and
WHEREAS, Hepatitis B is most prevalent among people of Asian and Pacific Islander descent, and one-third of Americans of Asian and Pacific Islander descent live in California; and
WHEREAS, Hepatitis B-related and hepatitis C-related hospitalization charges totaled $2.3 billion in 2010 in California, mostly paid for by tax-supported public health insurers; and
WHEREAS, New medications can cure hepatitis C in over 90 percent of people who are linked to and retained in care and treatment; and
WHEREAS, Hepatitis B can be treated effectively with proper medical management and may be curable in the near future; and
WHEREAS, The Legislature will continue to work to increase the affordability of, and access to, care, treatment, and cures for hepatitis; and
WHEREAS, Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California; and
WHEREAS, Hepatitis C is the most prevalent bloodborne disease in the United States and in California; and
WHEREAS, Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives; and
WHEREAS, An undetected and untreated hepatitis B or C infection can lead to disability or death; and
WHEREAS, The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure; and
WHEREAS, Untreated hepatitis B and C infections are the leading causes of liver failure requiring liver transplant; and
WHEREAS, While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C-related death toll now exceeds all other nationally notifiable infectious conditions combined; and
WHEREAS, Between 2011 and 2015, rates of newly reported hepatitis C infections increased 37 percent among females between 20 and 29 years of age, and 55 percent among males in that age rage, and increased 40 percent among males between 15 and 19 years of age; and
WHEREAS, Each year, hepatitis B and C cause nearly 1.5 million deaths worldwidemore than HIV, tuberculosis, and malaria; and
WHEREAS, On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030; and
WHEREAS, The federal Centers for Disease Control and Prevention released updated guidelines calling for baby boomerseveryone born between 1945 and 1965to receive a one-time hepatitis C test, which would save over 100,000 lives; and
WHEREAS, In 2013, the United States Preventive Services Task Force (USPSTF) issued a Grade B rating for screening for hepatitis C virus (HCV) infection in persons at high risk for infection and adults born between 1945 and 1965; and
WHEREAS, Baby boomers make up 30 percent of Californias adult population, and African American baby boomers are twice as likely to have hepatitis C as other baby boomers; and
WHEREAS, In 2009, the USPSTF issued a Grade A rating for screening pregnant women for the hepatitis B virus (HBV) infection during their first prenatal visit; and
WHEREAS, In 2014, the USPSTF issued a Grade B rating for screening people born in countries where hepatitis B is common, United States-born people who were not vaccinated against hepatitis B when they were babies and whose parents come from countries where hepatitis B is common, and other people at risk for hepatitis B; and
WHEREAS, There is a vaccine for the prevention of hepatitis Bthe first proven, low-cost vaccination against any form of cancer made available to Americans; and
WHEREAS, Hepatitis B is most prevalent among people of Asian and Pacific Islander descent, and one-third of Americans of Asian and Pacific Islander descent live in California; and
WHEREAS, Hepatitis B-related and hepatitis C-related hospitalization charges totaled $2.3 billion in 2010 in California, mostly paid for by tax-supported public health insurers; and
WHEREAS, New medications can cure hepatitis C in over 90 percent of people who are linked to and retained in care and treatment; and
WHEREAS, Hepatitis B can be treated effectively with proper medical management and may be curable in the near future; and
WHEREAS, The Legislature will continue to work to increase the affordability of, and access to, care, treatment, and cures for hepatitis; and
WHEREAS, Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| Jun 13, 2018 | Chaptered by Secretary of State - Res. Chapter 90, Statutes of 2018. |
| Jun 13, 2018 | Enrolled and filed with the Secretary of State at 11 a.m. |
| Jun 7, 2018 | In Assembly. Ordered to Engrossing and Enrolling. |
| Jun 7, 2018 | Adopted and to Assembly. |
| Jun 6, 2018 | Ordered to special consent calendar. |
| May 30, 2018 | From committee: Ordered to third reading. |
| May 21, 2018 | In Senate. To Com. on RLS. |
| May 17, 2018 | Coauthors revised. |
| May 9, 2018 | Re-referred to Com. on RLS. |
| May 14, 2018 | From committee: Be adopted. Ordered to Third Reading. (Ayes 8. Noes 0.) (May 14). |
| May 8, 2018 | From committee chair, with author's amendments: Amend, and re-refer to Com. on RLS. Amended. |
| Feb 26, 2018 | Referred to Com. on RLS. |
| Feb 14, 2018 | From printer. |
| Feb 13, 2018 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 7, 2018 | Special Consent ACR174 | Senate Floor |
Passed |
|
| May 14, 2018 | Be adopted. To third reading. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| California Hepatitis Alliance | ** Support | May 30, 2018 |
| Project Inform | ** Support | May 30, 2018 |
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | ACR 174 |
THIRD READING
Bill No: ACR 174
Amended: 5/8/18 in Assembly
ASSEMBLY FLOOR: Read and adopted, 5/17/18
SUBJECT: Hepatitis Awareness Month and Hepatitis Testing Day
SOURCE: California Hepatitis Alliance
Project Inform
DIGEST:
This resolution proclaims the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
ANALYSIS: This resolution makes the following legislative findings:
- Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California.
- Hepatitis C is the most prevalent bloodborne disease in the United States and in California.
- Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives.
- An undetected and untreated hepatitis B or C infection can lead to disability or death.
- Untreated hepatitis B and C infections are the leading causes of liver failure requiring a liver transplant.
- While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C-related death toll now exceeds all other nationally notifiable infectious conditions combined.
- Each year, hepatitis B and C cause nearly 1.5 million deaths worldwide—more than HIV, tuberculosis, and malaria.
- The federal Centers for Disease Control and Prevention released updated guidelines calling for baby boomers—everyone born between 1945 and 1965—to receive a one-time hepatitis C test, which would save over 100,000 lives.
- There is a vaccine for the prevention of hepatitis B—the first proven, low-cost vaccination against any form of cancer made available to Americans.
- New medications can cure hepatitis C in over 90 percent of people who are linked to and retained in care and treatment.
- Hepatitis B can be treated effectively with proper medical management and may be curable in the near future.
This resolution proclaims May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day.
Related/Prior Legislation
ACR 84 (Gipson, Resolution Chapter 74, Statutes of 2017) proclaimed the month of May 2017 as Hepatitis Awareness Month and May 19, 2017, as Hepatitis Testing Day.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
California Hepatitis Alliance (co-source)
Project Inform (co-source)
OPPOSITION: (Verified 5/29/18)
Prepared by: Karen Chow / SFA / (916) 651-1520
5/30/18 20:34:30
**** END ****
ASSEMBLY THIRD READING
ATR Bill Id:ACR 174
Author:(Gipson)
As Amended Ver:May 8, 2018
Majority vote
Committee | Votes | Ayes | Noes |
Rules | 8-0 | Cooley, Cunningham, Carrillo, Cervantes, Grayson, Nazarian, Salas, Waldron |
SUMMARY: Proclaims the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day. Specifically, this resolution makes the following legislative findings:
- Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California and hepatitis C is the most prevalent bloodborne disease in the United States and California.
- Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives. Left undetected and untreated, hepatitis B or C infection can lead to disability or death.
- The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure.
- The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure.
- While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C related death toll now exceeds all other nationally notifiable infectious conditions combined.
- Each year, hepatitis B and C cause nearly 1.5 million deaths worldwide, more than Human Immunodeficiency Virus, tuberculosis, and malaria.
- On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released "A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report" outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030.
- Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally.
FISCAL EFFECT: None
Analysis Prepared by: Nicole Willis / RLS. / (916) 319-2800 FN: 0002924
Date of Hearing: May 14, 2018
ASSEMBLY COMMITTEE ON RULES
Ken Cooley, Chair
ABPCA Bill Id:ACR 174
Author:(Gipson) – As Amended Ver:May 8, 2018
SUBJECT:
SUMMARY: Proclaims the month of May 2018 as Hepatitis Awareness Month and May 19, 2018, as Hepatitis Testing Day. Specifically, this resolution makes the following legislative findings:
- Liver cancer and liver disease related to hepatitis B and C are two of the leading killers in California and hepatitis C is the most prevalent bloodborne disease in the United States and California.
- Early detection of hepatitis B and C infections promotes effective management or treatment of these infections, preventing disability, loss of productivity and income, and allowing people to live full, satisfying, and productive lives. Left undetected and untreated, hepatitis B or C infection can lead to disability or death.
- The majority of the estimated 400,737 Californians with chronic hepatitis C infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure.
- The majority of the estimated 350,000 California residents with hepatitis B infection do not know they are infected, and are therefore at high risk of severe liver disease, liver cancer, or liver failure.
- While deaths from other notifiable infectious diseases have steadily declined over the past decade, deaths from hepatitis C in the United States continue to rise, and the hepatitis C related death toll now exceeds all other nationally notifiable infectious conditions combined.
- Each year, hepatitis B and C cause nearly 1.5 million deaths worldwide, more than HIV, tuberculosis, and malaria.
- On March 28, 2017, the National Academies of Sciences, Engineering, and Medicine released “A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report” outlining how the United States can save 90,000 lives and eliminate hepatitis B and C by 2030.
- Hepatitis awareness education campaigns and accessible screening for hepatitis B and C, along with appropriate treatment, can reduce the damage from hepatitis B and C viral infection to individuals and to our community, financially, as well as physically and emotionally.
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: Nicole Willis / RLS. / (916) 319-2800
Bill Author
Bill Co-Author(s):